BC patients with high expression of SLC12A8 had remarkably shorter overall survival than those in the low expression group both in TCGA (P = 0.014, Figure 2a) and GES13507 cohort (P = 0.0081, Figure 2b). Here, SLC12A8 is linked to breast cancer.